{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:12:59Z","timestamp":1792696379930,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.leukres.2022.106844","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:19:51Z","timestamp":1650860391000},"page":"106844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia"],"prefix":"10.1016","volume":"117","author":[{"given":"Sankalp","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Zainaldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srilakshmi","family":"Bathini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Worth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Godby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanti","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh D.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Stasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2022.106844_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ajh.25369","article-title":"Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use","volume":"94","author":"Mei","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106844_bib2","unstructured":"U.S. Food & Drug Administration, 2019.\u00a0FDA approves venetoclax in combination for AML in adults. December 17, 2018. 2019."},{"issue":"1","key":"10.1016\/j.leukres.2022.106844_bib3","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/16078454.2020.1843752","article-title":"The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"25","author":"Guo","year":"2020","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.leukres.2022.106844_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106844_bib5","unstructured":"U.S. Food, Drug Administration, 2018.Highlights of Prescribing Information: Venclexta; 2018.\" 2018."},{"issue":"1","key":"10.1016\/j.leukres.2022.106844_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106844_bib7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2022.106844_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.649209","article-title":"Outcomes of adults with relapsed\/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center","volume":"11","author":"Tenold","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106844_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2022.106844_bib10","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2020.1768384","article-title":"Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice","volume":"61","author":"Koehler","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2022.106844_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00277-021-04419-w","article-title":"Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort","volume":"100","author":"Bouclet","year":"2021","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2022.106844_bib12","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/13543784.2017.1386173","article-title":"Venetoclax for the treatment of chronic lymphocytic leukemia","volume":"26","author":"Gentile","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.leukres.2022.106844_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2022.106844_bib14","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2022.106844_bib15","first-page":"5323","article-title":"Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia","volume":"29","author":"Pelcovits","year":"2021","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2022.106844_bib16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00277-020-04181-5","article-title":"Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up","volume":"100","author":"Shahswar","year":"2021","journal-title":"Ann. Hematol."},{"issue":"15_suppl","key":"10.1016\/j.leukres.2022.106844_bib17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e19507","article-title":"Tumor lysis syndrome (TLS) in acute myeloid leukemia (AML) patients treated with azacitidine (AZA) and venetoclax (VEN)","volume":"38","author":"Huang","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2022.106844_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2022.106844_bib19","first-page":"43","article-title":"Update on the optimal use of voriconazole for invasive fungal infections","volume":"4","author":"Lat","year":"2011","journal-title":"Infect. Drug Resist."},{"issue":"4","key":"10.1016\/j.leukres.2022.106844_bib20","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bcp.13175","article-title":"Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma","volume":"83","author":"Agarwal","year":"2017","journal-title":"Br. J. Clin. Pharm."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:31Z","timestamp":1758934951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":20,"alternative-id":["S0145212622000704"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106844","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106844","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106844"}}